Skip to main content
Top
Published in: Diabetologia 7/2015

01-07-2015 | Letter

Comparison of HOMA-IR, HOMA-β% and disposition index between US white men and Japanese men in Japan in the ERA JUMP study: was the calculation of disposition index legitimate?

Authors: Keishi Yamauchi, Yuka Sato, Yasuto Nakasone, Toru Aizawa

Published in: Diabetologia | Issue 7/2015

Login to get access

Excerpt

To the Editor: Ahuja et al [1] determined insulin resistance and insulin secretion using HOMA-IR and HOMA of beta cell function (HOMA-β%), respectively, in white men living in the USA and Japanese men in Japan. They elegantly demonstrated that both HOMA-IR and HOMA-β% were significantly higher in the white men compared with the Japanese. In addition, they calculated disposition index (DI, in this case, oral disposition index) as a measure of beta cell function, i.e. HOMA-β% with the degree of insulin resistance being taken into consideration [2]. On the basis that the DI was higher in white than in Japanese people, the authors concluded that the higher DI in white men ‘may partly explain lower susceptibility of white people than Japanese people to developing type 2 diabetes’. We are afraid that there was a serious problem in the calculation of DI, and therefore the conclusion above may not be scientifically sound. The reason for this is as follows. In this study, DI was calculated as HOMA-β% divided by HOMA-IR, which is problematic. HOMA-β% = (FIRI × 20)/(FPG−3.5) [3], where FIRI denotes fasting immunoreactive insulin (μU/ml) and FPG denotes fasting plasma glucose (mmol/l). On the other hand, HOMA-IR = (FIRI × FPG)/22.5 [3]. Therefore, the DI defined by the authors, HOMA-β%/HOMA-IR = [(FIRI × 20)/(FPG−3.5)]/[(FIRI × FPG)/22.5], yields (20 × 22.5)/[(FPG)2 − (FPG × 3.5)] = 450/[(FPG)2 − (FPG × 3.5)] (Fig. 1). As can be seen, the DI thus calculated is simply a function of FPG, not an index of beta cell function. Therefore the DI calculated in the paper of Ahuja et al [1] was naturally higher in whites than in the Japanese individuals because FPG was lower in the former than in the latter. It is obvious that one cannot a priori assume that individuals with a low FPG have robust beta cell function and vice versa. The idea of defining DI as HOMA-β%/HOMA-IR might have arisen from the authors’ understanding that ‘DI is assumed to be hyperbolic (the constant product of insulin sensitivity and insulin secretion) for individuals with the same degree of glucose tolerance,’ which is not always correct [4, 5]. A hyperbolic relationship between indices of insulin sensitivity (SI) and insulin secretion exists for a certain combination of the two, but not for all combinations [4, 5]. There is certainly ethnic diversity, as inferred by Simonson et al [6], such that the relationship between the two in the Japanese population is different from that in white people [5]. It is strongly recommended that the legitimacy of the calculation of DI using any combination of indices of SI (or IR) and insulin secretion should be verified, before utilising the DI value as a measure of beta cell function.
Literature
1.
go back to reference Ahuja Y, Kadowaki T, Evans RW et al (2015) Comparison of HOMA-IR, HOMA-β% and disposition index between US white men and Japanese men in Japan: the ERA JUMP study. Diabetologia 58:265–271PubMedCrossRef Ahuja Y, Kadowaki T, Evans RW et al (2015) Comparison of HOMA-IR, HOMA-β% and disposition index between US white men and Japanese men in Japan: the ERA JUMP study. Diabetologia 58:265–271PubMedCrossRef
2.
go back to reference Utzschneider KM, Prigeon RL, Faulenbach MV et al (2009) Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32:335–341PubMedCentralPubMedCrossRef Utzschneider KM, Prigeon RL, Faulenbach MV et al (2009) Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32:335–341PubMedCentralPubMedCrossRef
3.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef
4.
go back to reference Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B (2008) Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity 16:1901–1907PubMedCrossRef Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B (2008) Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity 16:1901–1907PubMedCrossRef
5.
go back to reference Sato Y, Oka R, Nakasone Y, Katakura M, Yamauchi K, Aizawa T (2015) Impact of one-hour postchallenge glucose on the relationship between insulin sensitivity and secretion. Endocr J (in press) Sato Y, Oka R, Nakasone Y, Katakura M, Yamauchi K, Aizawa T (2015) Impact of one-hour postchallenge glucose on the relationship between insulin sensitivity and secretion. Endocr J (in press)
6.
go back to reference Simonson DC (2015) Surrogate measures of insulin resistance: does one size fit all? Diabetologia 58:207–10PubMedCrossRef Simonson DC (2015) Surrogate measures of insulin resistance: does one size fit all? Diabetologia 58:207–10PubMedCrossRef
Metadata
Title
Comparison of HOMA-IR, HOMA-β% and disposition index between US white men and Japanese men in Japan in the ERA JUMP study: was the calculation of disposition index legitimate?
Authors
Keishi Yamauchi
Yuka Sato
Yasuto Nakasone
Toru Aizawa
Publication date
01-07-2015
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 7/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3612-x

Other articles of this Issue 7/2015

Diabetologia 7/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.